Condition
EGFR Uncommon Mutations clinical trials and research
As of November 12, 2026, Find a Trial lists 2 EGFR Uncommon Mutations clinical trials that are recruiting, at sites in 17 countries (most in China (2), Australia (1), Canada (1)). By phase: Phase 2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 17Countries
All recruiting trials (2)
-
Firmonertinib with definitive radiotherapy for unresectable Stage III NSCLC with EGFR uncommon mutations
This trial tests whether adding Firmonertinib to definitive radiotherapy helps people with unresectable Stage III NSCLC that has uncommon EGFR mutations.
-
Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations
This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.
Related topics
Quick answers
How many EGFR Uncommon Mutations clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 17 countries. The most sites are in China (2 trials), Australia (1 trial), Canada (1 trial), France (1 trial), Greece (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.